Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Burning Rock Biotech Limited reported revenue of $77M, up 9.2% year over year. Operating margin was -10.2% and net margin -10.3%, on a free-cash-flow margin of -6.2% with capital expenditure at 1.0% of revenue. Every figure is computed directly from BNR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $77M | -10.2% | -10.3% |
| FY2024 | $71M | -69.3% | -67.2% |
| FY2023 | $76M | -124.5% | -121.6% |
| FY2022 | $82M | -174.1% | -172.4% |
| FY2021 | $80M | -156.9% | -156.9% |
How does BNR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.